

China approves world's first dual GCG/GLP-1 receptor agonist for weight loss

30 June 2025 | News

Mazdutide addresses a critical unmet need in China by offering effective treatment for weight reduction



Innovent Biologics, Inc. has announced that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity.

Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits.

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate intervention. In April 2025, the National Health Commission officially included "Healthy Weight Management Action" in the "Healthy China 2030" initiative. Under the updated plan, the national health authorities aim to build supportive environments for effective weight management, raise public awareness and behavior skills, and promote healthy lifestyles to curb rising rates of overweight and obesity.

Aligned with these national priorities and the 2025 weight management campaign, the approval of mazdutide represents a timely and important milestone. Aiming to be an innovative leader in the cardiovascular and metabolic (CVM) disease area, Innovent is committed to accelerating the delivery of this drug to benefit a broad population in China.

Mazdutide is supported by robust clinical data published in multiple high-impact journals, including *Nature*, the *Lancet* sub-journals, and the *New England Journal of Medicine*. As the first marketed dual GCG/GLP-1 receptor agonist, mazdutide has been recommended by multiple clinical guidelines in China and expert consensus on obesity management on account of its innovative mechanism and solid evidence base.